+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Generalized Anxiety Disorder Market Insight, Epidemiology and Market Forecast - 2032

  • PDF Icon

    Report

  • 160 Pages
  • January 2024
  • Region: Global
  • DelveInsight
  • ID: 5174534

Quick Summary:

In the ever-evolving landscape of healthcare and therapeutics, the market for Generalized Anxiety Disorder (GAD) treatments stands poised for significant transformation. As senior business executives overseeing investments in the burgeoning mental health sector, the insights contained within this comprehensive market research report could steer your decision-making process toward lucrative avenues.

The prevalence of Generalized Anxiety Disorder is on an upward trajectory, with current therapies opening paths to new, innovative treatments. A wide-reaching analysis of the existing treatment landscape and a forecasted market expansion serve as a beacon for strategic planning and investment. The therapeutic domain is witnessing exciting developments, including the introduction of pioneering therapies that promise to redefine the management of GAD.

The depth and caliber of the intelligence offered in this report encapsulate critical data on epidemiology, treatment algorithms, and the competitive environment. It meticulously dissects the profiles of emerging therapies poised for market entry, elucidating their clinical benefits and potential market impact. Delineating the epidemiological trends and pipeline prospects across key geographies, this analysis is an essential tool for maximizing your market position in the field of GAD therapeutics.

Key Highlights

  • The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies.
  • The analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 6,007,995 diagnosed prevalent cases of GAD.
  • In the 7MM, the market mainly consisted of standard treatments like SSRIs/SNRIs, Benzodiazepines, Tricyclic Antidepressants/Azapirone (Buspirone), and others (Antiepileptics, antipsychotics, etc.) which generated nearly USD 1,500 million in 2022.
  • The total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, MM-120 (LSD D-Tartrate), Fasedienol (PH94B), and others.
This “Generalized Anxiety Disorder (GAD) - Market Insights, Epidemiology, and Market Forecast - 2032” report delivers an in-depth understanding of the Generalized Anxiety Disorder (GAD), historical and forecasted epidemiology and the Generalized Anxiety Disorder (GAD) market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Generalized Anxiety Disorder (GAD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Generalized Anxiety Disorder (GAD) market size from 2019 to 2032. The report also covers current Generalized Anxiety Disorder (GAD) treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan
Study Period: 2019-2032

Disease Understanding and Treatment Algorithm

Generalized Anxiety Disorder (GAD) Overview

Generalized Anxiety Disorder (GAD) is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life.

The pathophysiology of Generalized Anxiety Disorder (GAD) is associated with dysregulation in neurotransmitter systems, particularly involving imbalances in serotonin, gamma-aminobutyric acid (GABA), and norepinephrine. Structural and functional alterations in brain regions such as the amygdala, prefrontal cortex, and limbic system contribute to heightened reactivity to stressors, impaired emotional regulation, and the persistent, excessive worry characteristic of GAD.

Generalized Anxiety Disorder (GAD) Diagnosis

The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs.

Generalized Anxiety Disorder (GAD) Treatment

The primary treatment goal for Generalized Anxiety Disorder (GAD) is to alleviate symptoms and improve overall functioning, aiming for a reduction in excessive and uncontrollable worry. Therapeutic interventions, including psychotherapy (such as cognitive-behavioral therapy) and pharmacotherapy (commonly with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors), are employed to achieve symptom relief, enhance coping mechanisms, and improve the individual's quality of life. Additionally, treatment strategies often focus on preventing relapse and managing coexisting conditions to support long-term well-being.

Generalized Anxiety Disorder (GAD) Epidemiology

As the market is derived using the patient-based model, the Generalized Anxiety Disorder (GAD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Generalized Anxiety Disorder (GAD), Gender-specific Diagnosed Prevalent cases of Generalized Anxiety Disorder (GAD), Age-specific Diagnosed Prevalent cases of Generalized Anxiety Disorder (GAD), and Severity-specific Diagnosed Prevalent cases of Generalized Anxiety Disorder (GAD) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per the estimations, the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in the 7MM was approximately 15,743,000 in 2022 and are projected to increase during the forecast period.
  • The overall count of individuals diagnosed with Generalized Anxiety Disorder (GAD) in the United States was approximately 8,418,000 in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2019-2023).
  • Among EU4 and the UK, Germany had the highest diagnosed prevalent population of GAD, with 1,410,000 cases, followed by Italy and Spain in 2022. On the other hand, the UK had the lowest prevalent population in the European region in 2022.
  • In 2022, Japan reported approximately 1,317,000 diagnosed prevalent cases of Generalized Anxiety Disorder (GAD), with expectations of a modest decline in these cases.
  • Gender-specific diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) showed that females were more affected by Generalized Anxiety Disorder (GAD) than males in the 7MM in 2022.
  • As per the analysis, the diagnosed prevalent cases of GAD based on age were categorized into four groups: 18-29 years, 30-44 years, 45-59 years, and 60 years and above. The highest proportion of Generalized Anxiety Disorder (GAD) cases was estimated in the 45-59 years age group in the 7MM, while the least cases were in the age group 18-29 years.
  • The cases of Generalized Anxiety Disorder (GAD) were classified based on severity levels, including mild, moderate, and severe. The publisher's estimations reveal that the highest number of severity-specific cases in the 7MM was attributed to moderate cases, totaling 6,811,000.

Generalized Anxiety Disorder (GAD) Drug Chapters

The drug chapter segment of the Generalized Anxiety Disorder (GAD) report encloses a detailed analysis of Generalized Anxiety Disorder (GAD) marketed drugs and mid-late stage (Phase III and Phase II) pipeline drugs. It also understands Generalized Anxiety Disorder (GAD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Fasedienol (PH94B): VistaGen Therapeutics

PH94B presents a promising advancement in the GAD pipeline, characterized by its rapid onset, sustained therapeutic effect, and the convenience of a single administration. These attributes not only address the critical need for quicker relief in anxiety disorders but also enhance patient compliance. The unique profile of PH94B, combined with its potential to offer a durable response with minimal dosing, positions it as a valuable innovation in the treatment landscape for GAD. These factors underscores the compound's potential to redefine standards in anxiety disorder management, potentially providing a more efficient and patient-friendly alternative for individuals grappling with GAD.

MM-120 (LSD D-Tartrate): MindMed

MM-120 (LSD D-Tartrate) is under clinical development by MindMed, Inc. and is currently in Phase II for GAD treatment. Administered orally, it is a pharmacologically enhanced version of lysergic acid diethylamide (LSD). This candidate has promising and enduring benefits against symptoms of anxiety and depression.

Note: Detailed emerging therapies assessment will be provided in the final report of Generalized Anxiety Disorder (GAD).

Generalized Anxiety Disorder (GAD) Market Outlook

Generalized Anxiety Disorder (GAD) has a diverse treatment classification associated with the disease landscape. The standard array of pharmacological agents employed in the management of GAD encompasses a diverse range, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antiepileptic's like pregabalin, tricyclic antidepressants (TCAs) that impact mood regulation, benzodiazepines offering rapid relief, antihistamines, atypical antipsychotics, and antioxidants.

The market for Generalized Anxiety Disorder (GAD) is expected to experience positive growth with the approval of potential drugs like Fasedienol, MM-120, and others.
  • The Generalized Anxiety Disorder (GAD) market's total size in the 7MM reached approximately USD 1,500 million in 2022. Projections indicate a substantial growth during the forecast period.
  • Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 64%.
  • In 2022, EU4 and the UK captured an estimated USD 443 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by Italy, and Spain.
  • Japan alone represented approximately 7% of the total Generalized Anxiety Disorder (GAD) market in 2022, projected to increase at a substantial CAGR during the study period.
  • The total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Generalized Anxiety Disorder (GAD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, Fasedienol in the US is expected to be launch by 2027.

Further detailed analysis of emerging therapies drug uptake in the report.

Generalized Anxiety Disorder (GAD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Generalized Anxiety Disorder (GAD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Generalized Anxiety Disorder (GAD) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, LA; Clinical Mental Health Supervisor, Western Pennsylvania; Max-Planck-Institute of Psychiatry, Unit Clinical Psychology and Epidemiology, Germany; Department of Neuroscience and Imaging, University 'G. d'Annunzio', Chieti , Italy; National Center of Neurology and Psychiatry, Tokyo, Japan, and others.

This analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Generalized Anxiety Disorder (GAD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

The publisher performs Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Generalized Anxiety Disorder (GAD), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
  • Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
  • A detailed review of the Generalized Anxiety Disorder (GAD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Generalized Anxiety Disorder (GAD) market.

Generalized Anxiety Disorder (GAD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Generalized Anxiety Disorder (GAD) Pipeline Analysis
  • Generalized Anxiety Disorder (GAD) Market Size and Trends
  • Existing and Future Market Opportunity

Generalized Anxiety Disorder (GAD) Report Key Strengths

  • 10 years Forecast
  • The 7MM Coverage
  • Generalized Anxiety Disorder (GAD) Epidemiology Segmentation
  • Key Cross Competition
  • Conjoint Analysis
  • Drugs Uptake and Key Market Forecast Assumptions

Generalized Anxiety Disorder (GAD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered

Market Insights

  • What was the Generalized Anxiety Disorder (GAD) total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
  • What unmet needs are associated with the current treatment market of Generalized Anxiety Disorder (GAD)?
  • What are the patents of emerging therapies for Generalized Anxiety Disorder (GAD)?
  • Which drug is going to be the largest contributor by 2032?
  • What are the pricing variations among different geographies for approved and off-label therapies?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

  • What are the disease risks, burdens, and unmet needs of Generalized Anxiety Disorder (GAD)? What will be the growth opportunities across the 7MM concerning the patient population of Generalized Anxiety Disorder (GAD)?
  • What is the historical and forecasted Generalized Anxiety Disorder (GAD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
  • Why do only limited patients appear for diagnosis?
  • Which country is more prevalent for Generalized Anxiety Disorder (GAD) and why?
  • What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What are the current options for treating Generalized Anxiety Disorder (GAD)? What are the current guidelines for treating Generalized Anxiety Disorder (GAD) in the US and Europe?
  • How many companies are developing therapies for treating Generalized Anxiety Disorder (GAD)?
  • How many emerging therapies are in the mid-stage and late stage of development for treating Generalized Anxiety Disorder (GAD)?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
  • What are the key designations that have been granted for the emerging therapies for Generalized Anxiety Disorder (GAD)?
  • Patient acceptability in terms of preferred treatment options as per real-world scenarios?
  • What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
  • What are the 7MM historical and forecasted markets of Generalized Anxiety Disorder (GAD)?

Reasons to Buy

  • The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Generalized Anxiety Disorder (GAD) Market.
  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
  • Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
  • Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
  • To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?
The Generalized Anxiety Disorder (GAD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2032, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Generalized Anxiety Disorder (GAD) market?
The Generalized Anxiety Disorder (GAD) market is very scare. The major players are VistaGen Therapeutics; MindMed, and others which are currently developing drugs for the treatment of Generalized Anxiety Disorder (GAD).

3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Generalized Anxiety Disorder (GAD) market?
The increase in diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) and launch of emerging therapies are attributed to be the key drivers for increasing Generalized Anxiety Disorder (GAD) market.

5. What is the expected impact of emerging therapies or advancements in Generalized Anxiety Disorder (GAD) treatment on the market?
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Generalized Anxiety Disorder (GAD) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Generalized Anxiety Disorder (GAD) market.

Table of Contents

1. Key Insights2. Report Introduction
3. Generalized Anxiety Disorder (GAD) Market Overview at a Glance
3.1. Market Share (%) Distribution by Therapies of GAD in 2019
3.2. Market Share (%) Distribution by Therapies of GAD in 2032
4. Epidemiology and Market Methodology of GAD5. Executive Summary of Generalized Anxiety Disorder (GAD)6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Causes and Risk Factors
7.3. Signs and Symptoms
7.4. Pathophysiology
7.5. Diagnosis
7.5.1. Diagnostic Algorithm
7.5.2. Screening Tools
7.6. Treatment and Management of Generalized Anxiety Disorder
7.6.1. Treatment of special populations
7.6.2. Treatment Algorithm
7.6.3. Treatment Guidelines
7.6.3.1. Recommendations as per American Family Physician
7.6.3.2. National Institute for Health and Care Excellence (NICE): GAD Management
7.6.3.3. Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical Practice Guideline for Social Anxiety Disorder (2021)
7.6.4. Treatment Recommendation Summary
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale of GAD
8.2.1. The United States
8.2.2. EU4 and the UK
8.2.3. Japan
8.3. Total Diagnosed Prevalent Cases of GAD in the 7MM
8.4. The United States
8.4.1. Total Diagnosed Prevalent Cases of GAD in the US
8.4.2. Gender-specific Diagnosed Prevalent Cases of GAD in the US
8.4.3. Age-specific Diagnosed Prevalent Cases of GAD in the US
8.4.4. Severity-specific Diagnosed Prevalent Cases of GAD in the US
8.5. EU4 and the UK
8.5.1. Germany
8.5.1.1. Total Diagnosed Prevalent Cases of GAD in Germany
8.5.1.2. Gender-specific Diagnosed Prevalent Cases of GAD in Germany
8.5.1.3. Age-specific Diagnosed Prevalent Cases of GAD in Germany
8.5.1.4. Severity-specific Diagnosed Prevalent Cases of GAD in Germany
8.5.2. France
8.5.2.1. Total Diagnosed Prevalent Cases of GAD in France
8.5.2.2. Gender-specific Diagnosed Prevalent Cases of GAD in France
8.5.2.3. Age-specific Diagnosed Prevalent Cases of GAD in France
8.5.2.4. Severity-specific Diagnosed Prevalent Cases of GAD in France
8.5.3. Italy
8.5.3.1. Total Diagnosed Prevalent Cases of GAD in Italy
8.5.3.2. Gender-specific Diagnosed Prevalent Cases of GAD in Italy
8.5.3.3. Age-specific Diagnosed Prevalent Cases of GAD in Italy
8.5.3.4. Severity-specific Diagnosed Prevalent Cases of GAD in Italy
8.5.4. Spain
8.5.4.1. Total Diagnosed Prevalent Cases of GAD in Spain
8.5.4.2. Gender-specific Diagnosed Prevalent Cases of GAD in Spain
8.5.4.3. Age-specific Diagnosed Prevalent Cases of GAD in Spain
8.5.4.4. Severity-specific Diagnosed Prevalent Cases of GAD in Spain
8.5.5. The UK
8.5.5.1. Total Diagnosed Prevalent Cases of GAD in the UK
8.5.5.2. Gender-specific Diagnosed Prevalent Cases of GAD in the UK
8.5.5.3. Age-specific Diagnosed Prevalent Cases of GAD in the UK
8.5.5.4. Severity-specific Diagnosed Prevalent Cases of GAD in the UK
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of GAD in Japan
8.6.2. Gender-specific Diagnosed Prevalent Cases of GAD in Japan
8.6.3. Age-specific Diagnosed Prevalent Cases of GAD in Japan
8.6.4. Severity-specific Diagnosed Prevalent Cases of GAD in Japan
9. Patient Journey of GAD
10. Emerging Therapies
10.1. Key Cross Competition
10.2. Fasedienol (PH94B): VistaGen Therapeutics
10.2.1. Product Description
10.2.2. Other Development Activities
10.2.3. Clinical development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.2.7. Analysts’ Views
10.3. MM-120: MindMed
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical development
10.3.4. Clinical Trials Information
10.3.5. Product Profile
10.3.6. Analysts’ Views
10.4. SEP-363856 (Ulotaront): Sumitomo Pharma America, Inc./Otsuka Pharmaceutical Co., Ltd/Sunovion Pharmaceuticals Inc.
10.4.1. Product Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Product Profile
10.4.6. Analysts’ Views
10.5. CYB004: Cybin IRL Limited
10.5.1. Product Description
10.5.2. Other Development Activities
10.5.3. Clinical Development
10.5.4. Clinical Trials Information
10.5.5. Product Profile
10.5.6. Analysts’ Views
10.6. ENX-102: Engrail Therapeutics INC
10.6.1. Product Description
10.6.2. Other Development Activities
10.6.3. Clinical Development
10.6.4. Clinical Trials Information
10.6.5. Product Profile
10.6.6. Analysts’ Views
10.7. BNC210: Bionomics Limited
10.7.1. Product Description
10.7.2. Other Development Activities
10.7.3. Clinical Development
10.7.4. Clinical Trials Information
10.7.5. Safety and Efficacy
10.7.6. Product Profile
10.7.7. Analysts’ Views
10.8. RLS103: Receptor Life Sciences/MannKind Corporation
10.8.1. Product Description
10.8.2. Other Development Activities
10.8.3. Clinical Development
10.8.4. Clinical Trials Information
10.8.5. Product Profile
10.8.6. Analysts’ Views
11. GAD: Market Analysis
11.1. Key Findings
11.2. Key Market Forecast Assumptions
11.3. Market Outlook
11.4. Total Market Size of GAD in the 7MM
11.5. Market Size of GAD by Therapies in the 7MM
11.6. Market Size of GAD in the United States
11.6.1. Total Market Size of GAD
11.6.2. Market Size of GAD by Therapies in the United States
11.7. Market Size of GAD in EU4 and the UK
11.7.1. Germany
11.7.1.1. Total Market Size of GAD
11.7.1.2. Market Size of GAD by Therapies in Germany
11.7.2. France
11.7.2.1. Total Market Size of GAD
11.7.2.2. Market Size of GAD by Therapies in France
11.7.3. Italy
11.7.3.1. Total Market Size of GAD
11.7.3.2. Market Size of GAD by Therapies in Italy
11.7.4. Spain
11.7.4.1. Total Market Size of GAD
11.7.4.2. Market Size of GAD by Therapies in Spain
11.7.5. The UK
11.7.5.1. Total Market Size of GAD
11.7.5.2. Market Size of GAD by Therapies in the UK
11.8. Market Size of GAD in Japan
11.8.1. Total Market Size of GAD
11.8.2. Market Size of GAD by Therapies in Japan
12. Key Opinion Leaders’ Views13. SWOT Analysis14. Unmet Needs
15. Market Access and Reimbursement
15.1. The United States
15.1.1. Center for Medicare and Medicaid Services (CMS)
15.2. In EU4 and the UK
15.2.1. Germany
15.2.2. France
15.2.3. Italy
15.2.4. Spain
15.2.5. The United Kingdom
15.3. Japan
15.3.1. MHLW
16. Appendix
16.1. Bibliography
16.2. Acronyms and Abbreviations
16.3. Report Methodology
17. Publisher Capabilities18. Disclaimer
List of Tables
Table 1: Summary of GAD Epidemiology and Market (2019-2032)
Table 2: Key Events
Table 3: “Normal” Worry Versus Generalized Anxiety Disorder
Table 4: Characteristics to Define GAD in DSM-V
Table 5: Evolution of the Definition of GAD in Succeeding Editions Of the DSM and ICD
Table 6: Treatment Approach to GAD
Table 7: Evidence rating
Table 8: Key Recommendations for Practice
Table 9: The Stepped-care Model
Table 10: Treatment Recommendations Summary
Table 11: Total Diagnosed Prevalent Cases of GAD in the 7MM, in ‘000’ (2019-2032)
Table 12: Total Diagnosed Prevalent Cases of GAD in the US, in ‘000’ (2019-2032)
Table 13: Gender-specific Diagnosed Prevalent Cases of GAD in the US, in ‘000’ (2019-2032)
Table 14: Age-specific Diagnosed Prevalent Cases of GAD in the US, in ‘000’ (2019-2032)
Table 15: Severity-specific Diagnosed Prevalent Cases of GAD in the US, in ‘000’ (2019-2032)
Table 16: Total Diagnosed Prevalent Cases of GAD in Germany, in ‘000’ (2019-2032)
Table 17: Gender-specific Diagnosed Prevalent Cases of GAD in Germany, in ‘000’ (2019-2032)
Table 18: Age-specific Diagnosed Prevalent Cases of GAD in Germany, in ‘000’ (2019-2032)
Table 19: Severity-specific Diagnosed Prevalent Cases of GAD in Germany, in ‘000’ (2019-2032)
Table 20: Total Diagnosed Prevalent Cases of GAD in France, in ‘000’ (2019-2032)
Table 21: Gender-specific Diagnosed Prevalent Cases of GAD in France, in ‘000’ (2019-2032)
Table 22: Age-specific Diagnosed Prevalent Cases of GAD in France, in ‘000’ (2019-2032)
Table 23: Severity-specific Diagnosed Prevalent Cases of GAD in France, in ‘000’ (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of GAD in Italy, in ‘000’ (2019-2032)
Table 25: Gender-specific Diagnosed Prevalent Cases of GAD in Italy, in ‘000’ (2019-2032)
Table 26: Age-specific Diagnosed Prevalent Cases of GAD in Italy, in ‘000’ (2019-2032)
Table 27: Severity-specific Diagnosed Prevalent Cases of GAD in Italy, in ‘000’ (2019-2032)
Table 28: Total Diagnosed Prevalent Cases of GAD in Spain, in ‘000’ (2019-2032)
Table 29: Gender-specific Diagnosed Prevalent Cases of GAD in Spain, in ‘000’ (2019-2032)
Table 30: Age-specific Diagnosed Prevalent Cases of GAD in Spain, in ‘000’ (2019-2032)
Table 31: Severity-specific Diagnosed Prevalent Cases of GAD in Spain, in ‘000’ (2019-2032)
Table 32: Total Diagnosed Prevalent Cases of GAD in the UK, in ‘000’ (2019-2032)
Table 33: Gender-specific Diagnosed Prevalent Cases of GAD in the UK, in ‘000’ (2019-2032)
Table 34: Age-specific Diagnosed Prevalent Cases of GAD in the UK, in ‘000’ (2019-2032)
Table 35: Severity-specific Diagnosed Prevalent Cases of GAD in the UK, in ‘000’ (2019-2032)
Table 36: Total Diagnosed Prevalent Cases of GAD in EU4 and the UK, in ‘000’ (2019-2032)
Table 37: Gender-specific Diagnosed Prevalent Cases of GAD in EU4 and the UK, in ‘000’ (2019-2032)
Table 38: Age-specific Diagnosed Prevalent Cases of GAD in EU4 and the UK, in ‘000’ (2019-2032)
Table 39: Severity-specific Diagnosed Prevalent Cases of GAD in EU4 and the UK, in ‘000’ (2019-2032)
Table 40: Total Diagnosed Prevalent Cases of GAD in Japan, in ‘000’ (2019-2032)
Table 41: Gender-specific Diagnosed Prevalent Cases of GAD in Japan, in ‘000’ (2019-2032)
Table 42: Age-specific Diagnosed Prevalent Cases of GAD in Japan, in ‘000’ (2019-2032)
Table 43: Severity-specific Diagnosed Prevalent Cases of GAD in Japan, in ‘000’ (2019-2032)
Table 44: Comparison of Emerging Drugs
Table 45: Fasedienol (PH94B), Clinical Trial Description, 2023
Table 46: MM-120, Clinical Trial Description, 2023
Table 47: SEP-363856; Clinical Trial Description, 2023
Table 48: CYB004; Clinical Trial Description, 2023
Table 49: ENX-102; Clinical Trial Description, 2023
Table 50: BNC210; Clinical Trial Description, 2023
Table 51: RLS103; Clinical Trial Description, 2023
Table 52: Key Market Forecast Assumptions for MM-120 (LSD D-Tartrate)
Table 53: Key Market Forecast Assumptions for Fasedienol (PH94B)
Table 54: Total Market Size of GAD in the 7MM, in USD million (2019-2032)
Table 55: Market Size by Therapies of GAD in the 7MM, in USD million (2019-2032)
Table 56: Total Market Size of GAD in the US, in USD million (2019-2032)
Table 57: Market Size by Therapies of GAD in the US, in USD million (2019-2032)
Table 58: Total Market Size of GAD in Germany (2019-2032)
Table 59: Market Size by Therapies of GAD in Germany, in USD million (2019-2032)
Table 60: Total Market Size of GAD in France (2019-2032)
Table 61: Market Size by Therapies of GAD in France, in USD million (2019-2032)
Table 62: Total Market Size of GAD in Italy (2019-2032)
Table 63: Market Size by Therapies of GAD in Italy, in USD million (2019-2032)
Table 64: Total Market Size of GAD in Spain (2019-2032)
Table 65: Market Size by Therapies of GAD in Spain, in USD million (2019-2032)
Table 66: Total Market Size of GAD in the UK (2019-2032)
Table 67: Market Size by Therapies of GAD in the UK, in USD million (2019-2032)
Table 68: Total Market Size of GAD in Japan, in USD million (2019-2032)
Table 69: Market Size by Therapies of GAD in Japan, in USD million (2019-2032)
List of Figures
Figure 1: Overview of GAD
Figure 2: Etiology of GAD
Figure 3: Risk Factors for GAD
Figure 4: Symptoms and Behaviors Associated With GAD
Figure 5: Assessment of Patients with Anxiety
Figure 6: Mental Disorders Screening - General Anxiety Disorder Assessment (GAD-7)
Figure 7: Mental Disorders Screening - Generalized Anxiety Disorder Assessment (GAD-2)
Figure 8: GAD Treatment Flow Chart
Figure 9: Cognitive Behavioral Therapy
Figure 10: Pharmacotherapy for GAD
Figure 11: Practice Algorithm for Social Anxiety Disorder
Figure 12: GAD Management Overview
Figure 13: Total Diagnosed Prevalent Cases of GAD in the 7MM (2019-2032)
Figure 14: Total Diagnosed Prevalent Cases of GAD in the US (2019-2032)
Figure 15: Gender-specific Diagnosed Prevalent Cases of GAD in the US (2019-2032)
Figure 16: Age-specific Diagnosed Prevalent Cases of GAD in the US (2019-2032)
Figure 17: Severity-specific Diagnosed Prevalent Cases of GAD in the US (2019-2032)
Figure 18: Total Diagnosed Prevalent Cases of GAD in Germany (2019-2032)
Figure 19: Gender-specific Diagnosed Prevalent Cases of GAD in Germany (2019-2032)
Figure 20: Age-specific Diagnosed Prevalent Cases of GAD in Germany (2019-2032)
Figure 21: Severity-specific Diagnosed Prevalent Cases of GAD in Germany (2019-2032)
Figure 22: Total Diagnosed Prevalent Cases of GAD in France (2019-2032)
Figure 23: Gender-specific Diagnosed Prevalent Cases of GAD in France (2019-2032)
Figure 24: Age-specific Diagnosed Prevalent Cases of GAD in France (2019-2032)
Figure 25: Severity-specific Diagnosed Prevalent Cases of GAD in France (2019-2032)
Figure 26: Total Diagnosed Prevalent Cases of GAD in Italy (2019-2032)
Figure 27: Gender-specific Diagnosed Prevalent Cases of GAD in Italy (2019-2032)
Figure 28: Age-specific Diagnosed Prevalent Cases of GAD in Italy (2019-2032)
Figure 29: Severity-specific Diagnosed Prevalent Cases of GAD in Italy (2019-2032)
Figure 30: Total Diagnosed Prevalent Cases of GAD in Spain (2019-2032)
Figure 31: Gender-specific Diagnosed Prevalent Cases of GAD in Spain (2019-2032)
Figure 32: Age-specific Diagnosed Prevalent Cases of GAD in Spain (2019-2032)
Figure 33: Severity-specific Diagnosed Prevalent Cases of GAD in Spain (2019-2032)
Figure 34: Total Diagnosed Prevalent Cases of GAD in the UK (2019-2032)
Figure 35: Gender-specific Diagnosed Prevalent Cases of GAD in the UK (2019-2032)
Figure 36: Age-specific Diagnosed Prevalent Cases of GAD in the UK (2019-2032)
Figure 37: Severity-specific Diagnosed Prevalent Cases of GAD in the UK (2019-2032)
Figure 38: Total Diagnosed Prevalent Cases of GAD in EU4 and the UK (2019-2032)
Figure 39: Gender-specific Diagnosed Prevalent Cases of GAD in EU4 and the UK (2019-2032)
Figure 40: Age-specific Diagnosed Prevalent Cases of GAD in EU4 and the UK (2019-2032)
Figure 41: Severity-specific Diagnosed Prevalent Cases of GAD in EU4 and the UK (2019-2032)
Figure 42: Total Diagnosed Prevalent Cases of GAD in Japan (2019-2032)
Figure 43: Gender-specific Diagnosed Prevalent Cases of GAD in Japan (2019-2032)
Figure 44: Age-specific Diagnosed Prevalent Cases of GAD in Japan (2019-2032)
Figure 45: Severity-specific Diagnosed Prevalent Cases of GAD in Japan (2019-2032)
Figure 46: Patient Journey
Figure 47: Total Market Size of GAD in the 7MM (2019-2032)
Figure 48: Market Size by Therapies of GAD in the 7MM (2019-2032)
Figure 49: Total Market Size of GAD in the US (2019-2032)
Figure 50: Market Size by Therapies of GAD in the US (2019-2032)
Figure 51: Total Market Size of GAD in Germany(2019-2032)
Figure 52: Market Size by Therapies of GAD in Germany(2019-2032)
Figure 53: Total Market Size of GAD in France(2019-2032)
Figure 54: Market Size by Therapies of GAD in France(2019-2032)
Figure 55: Total Market Size of GAD in Italy(2019-2032)
Figure 56: Market Size by Therapies of GAD in Italy(2019-2032)
Figure 57: Total Market Size of GAD in Spain(2019-2032)
Figure 58: Market Size by Therapies of GAD in Spain(2019-2032)
Figure 59: Total Market Size of GAD in the UK(2019-2032)
Figure 60: Market Size by Therapies of GAD in the UK(2019-2032)
Figure 61: Total Market Size of GAD in Japan (2019-2032)
Figure 62: Market Size by Therapies of GAD in Japan (2019-2032)
Figure 63: SWOT Analysis
Figure 64: Unmet Needs
Figure 65: Health Technology Assessment
Figure 66: Reimbursement Process in Germany
Figure 67: Reimbursement Process in France
Figure 68: Reimbursement Process in Spain
Figure 69: Reimbursement Process in the United Kingdom
Figure 70: Reimbursement Process in Japan

Companies Mentioned

A selection of companies mentioned in this report includes:

  • VistaGen Therapeutics
  • MindMed
  • Sumitomo Pharma America, Inc.
  • Otsuka Pharmaceutical Co., Ltd
  • Sunovion Pharmaceuticals Inc.
  • Cybin IRL Limited
  • Engrail Therapeutics INC
  • Bionomics Limited
  • Receptor Life Sciences
  • MannKind Corporation